Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib Combined With Cisplatin and Paclitaxel as First-line Chemotherapy for Recurrent or Persistent Advanced Cervical Cancer: A Single Arm, Single Center, Open, Phase II Trial

NCT04188847 is registered in ClinicalTrials.gov with Lei Li as lead sponsor.

NCT NCT04188847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04188847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib Combined With Cisplatin and Paclitaxel as First-line Chemotherapy for Recurrent or Persistent Advanced Cervical Cancer: A Single Arm, Single Center, Open, Phase II Trial
Lead sponsor
Lei Li
Phase
Phase 2
Overall status
Completed
Start date
December 6, 2019
Completion date
March 13, 2022
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

apatinib, chemotherapy, persistent advanced cervical carcinoma, recurrent cervical carcinoma, targeted therapy, vascular endothelial growth factor 2 inhibitor